Acyclovir as a Potential Adjuvant Therapy in COVID-19 Treatment Regimens

Abstract

Introduction: There are successful reports of the concomitant management of herpes infection and coronavirus disease 2019 (COVID-19), using both acyclovir (ACV) and COVID-19 treatment regimens. Furthermore, ACV has been proposed to effectively treat COVID-19, through various mechanisms, such as inhibition of viral proteases, multiple viral gene expressions, and RNA-dependent RNA polymerase (RdRP). Therefore, this study aimed to review the reported cases of patients with concomitant herpes infection and COVID-19, receiving concurrent antiviral drugs for herpetic lesions. Methods: A search was done to find the relevant articles, published between December 2019 and December 2020, with no language limitations, in the PubMed database, using the Medical Subject Headings (MeSH) terms related to herpes simplex virus or herpes zoster (namely, shingles) combined with COVID-19. Accordingly, the reports of the concomitant herpes infection and COVID-19, receiving concurrent antiviral drugs for herpetic lesions were included. Results: Out of 90 articles, 11 records reporting the cases of herpes infection and concurrent laboratory-confirmed COVID-19, receiving antiherpetic therapies, were reviewed. There were 28 patients (age range of 7-82 years) with laboratory-confirmed COVID-19, concomitant with reactivation of herpes infection, receiving antiviral drugs alongside candidate COVID-19 treatment regimens, but no mortality. The mean (standard deviation [SD] range) age of these 28 patients during treatment was 56.4 (18.6 [7-82]) years, and the majority were male (n=18, 64.3%). A total number of 20 patients had also received ACV and eight cases had been administered with other two antiviral compounds, including seven cases with valacyclovir, and one case with famciclovir, with no mortality. Conclusion: The potential use of ACV, as an add-on therapy, along with candidate COVID-19 treatment regimens was proposed in this study. However, further clinical trials are recommended to test this hypothetical adjuvant therapy.

Can Nitazoxanide and/or other anti‐viral medications be a solution to long COVID? Case report with a brief literature review

“…Recent studies illustrated significant correlations across COVID‐19, PASC and herpesviruses' reactivation, including Varicella‐Zoster (causing shingles), Epstein–Barr, HSV‐1 or Cytomegalovirus, attributed to COVID‐19‐induced lymphopenia 70–74 . For example, at the beginning of March 2021, aforementioned Patient‐Y suffered shingles, which might have been consequential of PASC.…”

Buchwald–Hartwig coupled conjugated microporous polymer for efficient removal COVID-19 antiviral drug famciclovir from waters: Adsorption behavior and mechanism

“…One of the antiviral drugs, famciclovir (FCV), is a ring-opening nucleoside drug mainly used to treat herpes virus infections [3] . Owing to the global presence of COVID-19, FCV was proposed as an add-on therapy after the onset of the coronavirus disease 2019 (COVID-19) along with COVID-19 treatments [4] , the environmental harm caused by the large-scale use and bioaccumulation of FCV is evident. Therefore, removing FCV from waterbodies should be promptly tackled.…”

Evaluation of acyclovir adsorption on granular activated carbon from aqueous solutions: batch and fixed-bed parametric studies

“…Therefore, the viral infections are of the global concern. Researchers are exploring new promising antibodies, antiviral treatments, and ways to improve the efficacy of existing medications on a laboratory scale (Al-Otaibi et al 2020;Heidary et al 2021;Guo et al 2022). Antiviral drugs have received a lot of attention recently (Nannou et al 2020;Jain et al 2013;De Clercq 2004).…”